Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

International Journal of Endocrinology Pub Date : 2024-02-13 DOI:10.1155/2024/9294113

Yuting Yuan, Yue Zhang, Min Lei, Xiying Guo, Xiaosong Yang, Changhan Ouyang, Chao Liu, Qingjie Chen

{"title":"Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review","authors":"Yuting Yuan, Yue Zhang, Min Lei, Xiying Guo, Xiaosong Yang, Changhan Ouyang, Chao Liu, Qingjie Chen","doi":"10.1155/2024/9294113","DOIUrl":null,"url":null,"abstract":"<i>Purpose</i>. Type 2 diabetes mellitus is considered as one of the risk factors for cognitive impairment. DPP4 inhibitors are effective drugs for the treatment of type 2 diabetes mellitus. However, the relationship between DPP4 inhibitors and cognitive dysfunction remains unclear. Therefore, we used a meta-analysis to determine the association between DPP4 inhibitors and cognitive impairment in type 2 diabetes mellitus. <i>Methods</i>. We systematically searched PubMed, CNKI, and the Cochrane Library at the time of establishment, 2022, and then made inclusion criteria and screened strategies to identify studies with more precise correlations. <i>Results</i>. We included 10 studies with 5,583 participants. The data showed that DPP4 inhibitors significantly reduced the incidence rate of cognitive impairment in type 2 diabetes mellitus (SMD: 0.99; 95% CI [0.59, 1.38]). Furthermore, there was a linear correlation found between cognitive impairment in type 2 diabetes mellitus and fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. DPP4 inhibitors decreased fasting blood glucose (FPG) (SMD: 0.52; 95% CI [−0.68, −0.37]), blood glucose (2hPPG) at 2 hours after the meal (SMD: 0.82; 95% CI, [−1.2, −0.43]), and HbA1c (SMD: 0.34; 95% CI [−0.48, −0.21]). All data were statistically significant (<span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.6359 19.289 9.2729\" width=\"19.289pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,11.658,0)\"></path></g></svg><span></span><span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"22.8711838 -8.6359 34.445 9.2729\" width=\"34.445pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.921,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,29.161,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,32.125,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.365,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.605,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,50.845,0)\"></path></g></svg>).</span></span> Furthermore, we conducted subgroup analyses of the following measures at various treatment durations and ages: cognitive scores, fasting blood glucose, glycosylated hemoglobin, and two-hour postprandial blood glucose. <i>Conclusion</i>. DPP4 inhibitors significantly improved type 2 diabetic mellitus individuals’ cognitive impairment and reduced fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. Subgroup analysis showed that people aged 60 to 70 years had better treatment effects at 0–180 days. This trial is registered with CRD42023399473.","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"5 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/9294113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose. Type 2 diabetes mellitus is considered as one of the risk factors for cognitive impairment. DPP4 inhibitors are effective drugs for the treatment of type 2 diabetes mellitus. However, the relationship between DPP4 inhibitors and cognitive dysfunction remains unclear. Therefore, we used a meta-analysis to determine the association between DPP4 inhibitors and cognitive impairment in type 2 diabetes mellitus. Methods. We systematically searched PubMed, CNKI, and the Cochrane Library at the time of establishment, 2022, and then made inclusion criteria and screened strategies to identify studies with more precise correlations. Results. We included 10 studies with 5,583 participants. The data showed that DPP4 inhibitors significantly reduced the incidence rate of cognitive impairment in type 2 diabetes mellitus (SMD: 0.99; 95% CI [0.59, 1.38]). Furthermore, there was a linear correlation found between cognitive impairment in type 2 diabetes mellitus and fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. DPP4 inhibitors decreased fasting blood glucose (FPG) (SMD: 0.52; 95% CI [−0.68, −0.37]), blood glucose (2hPPG) at 2 hours after the meal (SMD: 0.82; 95% CI, [−1.2, −0.43]), and HbA1c (SMD: 0.34; 95% CI [−0.48, −0.21]). All data were statistically significant (). Furthermore, we conducted subgroup analyses of the following measures at various treatment durations and ages: cognitive scores, fasting blood glucose, glycosylated hemoglobin, and two-hour postprandial blood glucose. Conclusion. DPP4 inhibitors significantly improved type 2 diabetic mellitus individuals’ cognitive impairment and reduced fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. Subgroup analysis showed that people aged 60 to 70 years had better treatment effects at 0–180 days. This trial is registered with CRD42023399473.

查看原文本刊更多论文

作为神经保护药物的 DPP4 抑制剂对 2 型糖尿病患者认知障碍的影响：元分析和系统综述

目的2 型糖尿病被认为是认知障碍的风险因素之一。DPP4 抑制剂是治疗 2 型糖尿病的有效药物。然而，DPP4 抑制剂与认知功能障碍之间的关系仍不清楚。因此，我们采用荟萃分析法来确定 DPP4 抑制剂与 2 型糖尿病认知功能障碍之间的关系。研究方法我们系统地检索了PubMed、CNKI和Cochrane图书馆2022年建立时的资料，然后制定了纳入标准和筛选策略，以确定具有更精确相关性的研究。结果显示我们纳入了 10 项研究，共有 5583 名参与者。数据显示，DPP4 抑制剂能显著降低 2 型糖尿病认知障碍的发病率（SMD：0.99；95% CI [0.59，1.38]）。此外，还发现 2 型糖尿病患者的认知障碍与空腹血糖、餐后 2 小时血糖和糖化血红蛋白之间存在线性相关。DPP4 抑制剂可降低空腹血糖（FPG）（SMD：0.52；95% CI [-0.68，-0.37]）、餐后 2 小时血糖（2hPPG）（SMD：0.82；95% CI [-1.2，-0.43]）和 HbA1c（SMD：0.34；95% CI [-0.48，-0.21]）。所有数据均具有统计学意义（）。此外，我们还对不同治疗时间和年龄段的以下指标进行了亚组分析：认知评分、空腹血糖、糖化血红蛋白和餐后两小时血糖。结论DPP4抑制剂能明显改善2型糖尿病患者的认知障碍，降低空腹血糖、餐后2小时血糖和糖化血红蛋白。亚组分析显示，60 至 70 岁的患者在 0-180 天的治疗效果更好。该试验的注册号为 CRD42023399473。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrinology ENDOCRINOLOGY & METABOLISM-

CiteScore

5.20

自引率

0.00%

发文量

147

审稿时长

1 months

期刊介绍： International Journal of Endocrinology is a peer-reviewed, Open Access journal that provides a forum for scientists and clinicians working in basic and translational research. The journal publishes original research articles, review articles, and clinical studies that provide insights into the endocrine system and its associated diseases at a genomic, molecular, biochemical and cellular level.